Cargando…

A nationwide analysis on the interaction between frailty and beta-blocker therapy in hip fracture patients

INTRODUCTION: Hip fracture patients, who are often frail, continue to be a challenge for healthcare systems with a high postoperative mortality rate. While beta-blocker therapy (BBt) has shown a strong association with reduced postoperative mortality, its effect in frail patients has yet to be deter...

Descripción completa

Detalles Bibliográficos
Autores principales: Forssten, Maximilian Peter, Mohammad Ismail, Ahmad, Ioannidis, Ioannis, Wretenberg, Per, Borg, Tomas, Cao, Yang, Ribeiro, Marcelo A. F., Mohseni, Shahin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229461/
https://www.ncbi.nlm.nih.gov/pubmed/36633610
http://dx.doi.org/10.1007/s00068-023-02219-7
_version_ 1785051259875622912
author Forssten, Maximilian Peter
Mohammad Ismail, Ahmad
Ioannidis, Ioannis
Wretenberg, Per
Borg, Tomas
Cao, Yang
Ribeiro, Marcelo A. F.
Mohseni, Shahin
author_facet Forssten, Maximilian Peter
Mohammad Ismail, Ahmad
Ioannidis, Ioannis
Wretenberg, Per
Borg, Tomas
Cao, Yang
Ribeiro, Marcelo A. F.
Mohseni, Shahin
author_sort Forssten, Maximilian Peter
collection PubMed
description INTRODUCTION: Hip fracture patients, who are often frail, continue to be a challenge for healthcare systems with a high postoperative mortality rate. While beta-blocker therapy (BBt) has shown a strong association with reduced postoperative mortality, its effect in frail patients has yet to be determined. This study’s aim is to investigate how frailty, measured using the Orthopedic Hip Frailty Score (OFS), modifies the effect of preadmission beta-blocker therapy on mortality in hip fracture patients. METHODS: This retrospective register-based study included all adult patients in Sweden who suffered a traumatic hip fracture and subsequently underwent surgery between 2008 and 2017. Treatment effect was evaluated using the absolute risk reduction (ARR) in 30-day postoperative mortality when comparing patients with (BBt+) and without (BBt-) ongoing BBt. Inverse probability of treatment weighting (IPTW) was used to reduce potential confounding when examining the treatment effect. Patients were stratified based on their OFS (0, 1, 2, 3, 4 and 5) and the treatment effect was also assessed within each stratum. RESULTS: A total of 127,305 patients were included, of whom 39% had BBt. When IPTW was performed, there were no residual differences in observed baseline characteristics between the BBt+ and BBt- groups, across all strata. This analysis found that there was a stepwise increase in the ARRs for each additional point on the OFS. Non-frail BBt+ patients (OFS 0) exhibited an ARR of 2.2% [95% confidence interval (CI) 2.0–2.4%, p < 0.001], while the most frail BBt+ patients (OFS 5) had an ARR of 24% [95% CI 18–30%, p < 0.001], compared to BBt- patients within the same stratum. CONCLUSION: Beta-blocker therapy is associated with a reduced risk of 30-day postoperative mortality in frail hip fracture patients, with a greater effect being observed with higher Orthopedic Hip Frailty Scores. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00068-023-02219-7.
format Online
Article
Text
id pubmed-10229461
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-102294612023-06-01 A nationwide analysis on the interaction between frailty and beta-blocker therapy in hip fracture patients Forssten, Maximilian Peter Mohammad Ismail, Ahmad Ioannidis, Ioannis Wretenberg, Per Borg, Tomas Cao, Yang Ribeiro, Marcelo A. F. Mohseni, Shahin Eur J Trauma Emerg Surg Original Article INTRODUCTION: Hip fracture patients, who are often frail, continue to be a challenge for healthcare systems with a high postoperative mortality rate. While beta-blocker therapy (BBt) has shown a strong association with reduced postoperative mortality, its effect in frail patients has yet to be determined. This study’s aim is to investigate how frailty, measured using the Orthopedic Hip Frailty Score (OFS), modifies the effect of preadmission beta-blocker therapy on mortality in hip fracture patients. METHODS: This retrospective register-based study included all adult patients in Sweden who suffered a traumatic hip fracture and subsequently underwent surgery between 2008 and 2017. Treatment effect was evaluated using the absolute risk reduction (ARR) in 30-day postoperative mortality when comparing patients with (BBt+) and without (BBt-) ongoing BBt. Inverse probability of treatment weighting (IPTW) was used to reduce potential confounding when examining the treatment effect. Patients were stratified based on their OFS (0, 1, 2, 3, 4 and 5) and the treatment effect was also assessed within each stratum. RESULTS: A total of 127,305 patients were included, of whom 39% had BBt. When IPTW was performed, there were no residual differences in observed baseline characteristics between the BBt+ and BBt- groups, across all strata. This analysis found that there was a stepwise increase in the ARRs for each additional point on the OFS. Non-frail BBt+ patients (OFS 0) exhibited an ARR of 2.2% [95% confidence interval (CI) 2.0–2.4%, p < 0.001], while the most frail BBt+ patients (OFS 5) had an ARR of 24% [95% CI 18–30%, p < 0.001], compared to BBt- patients within the same stratum. CONCLUSION: Beta-blocker therapy is associated with a reduced risk of 30-day postoperative mortality in frail hip fracture patients, with a greater effect being observed with higher Orthopedic Hip Frailty Scores. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00068-023-02219-7. Springer Berlin Heidelberg 2023-01-12 2023 /pmc/articles/PMC10229461/ /pubmed/36633610 http://dx.doi.org/10.1007/s00068-023-02219-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Forssten, Maximilian Peter
Mohammad Ismail, Ahmad
Ioannidis, Ioannis
Wretenberg, Per
Borg, Tomas
Cao, Yang
Ribeiro, Marcelo A. F.
Mohseni, Shahin
A nationwide analysis on the interaction between frailty and beta-blocker therapy in hip fracture patients
title A nationwide analysis on the interaction between frailty and beta-blocker therapy in hip fracture patients
title_full A nationwide analysis on the interaction between frailty and beta-blocker therapy in hip fracture patients
title_fullStr A nationwide analysis on the interaction between frailty and beta-blocker therapy in hip fracture patients
title_full_unstemmed A nationwide analysis on the interaction between frailty and beta-blocker therapy in hip fracture patients
title_short A nationwide analysis on the interaction between frailty and beta-blocker therapy in hip fracture patients
title_sort nationwide analysis on the interaction between frailty and beta-blocker therapy in hip fracture patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229461/
https://www.ncbi.nlm.nih.gov/pubmed/36633610
http://dx.doi.org/10.1007/s00068-023-02219-7
work_keys_str_mv AT forsstenmaximilianpeter anationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT mohammadismailahmad anationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT ioannidisioannis anationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT wretenbergper anationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT borgtomas anationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT caoyang anationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT ribeiromarceloaf anationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT mohsenishahin anationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT forsstenmaximilianpeter nationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT mohammadismailahmad nationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT ioannidisioannis nationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT wretenbergper nationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT borgtomas nationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT caoyang nationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT ribeiromarceloaf nationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients
AT mohsenishahin nationwideanalysisontheinteractionbetweenfrailtyandbetablockertherapyinhipfracturepatients